Letter to the Editor concerning ‘cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’-Reference-Cited by-同舟云学术

Letter to the Editor concerning ‘cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis’

Published:2024-08 Issue:1 Volume:38 Page:
ISSN:1310-2818
Container-title:Biotechnology & Biotechnological Equipment
language:en
Short-container-title:Biotechnology & Biotechnological Equipment

Author:

Stevenson A. L.¹,Chang-Douglass S.²,Kazmierska P.²,Benedict A.³,Azimpour K.⁴,Dorling P.⁵

Affiliation:

1. Health Economics and Outcomes Research, Global Rare Diseases, Chiesi Ltd, Manchester, UK

2. Modeling & Simulation, Evidence Synthesis, Modeling and Communication, Evidera Ltd, London, UK

3. Scientific Affairs, Modeling & Simulation, Evidence Synthesis, Modeling and Communication, Evidera Ltd, Budapest, Hungary

4. Health Economics and Outcome Research, Chiesi Canada Corp, Montreal, Canada

5. Head of Health Economics Outcome Research & Real World Evidence, Rare Diseases, Chiesi USA, Inc, Boston, MA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13102818.2024.2386487

Reference8 articles.

1. Cost-effectiveness of velmanase alfa vs. bone marrow transplantation or no causal therapy in patients with mild to moderate alpha-mannosidosis

2. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial

3. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis

4. Guffon N, editor Longterm efficacy of velmanase alfa treatment in patients with alphamannosidosis: pooled data from two extension studies (up to 12 years of therapy). 20th Annual WORLD Symposium; 2024 Feb 4–9; San Diego, CA.

5. Long-term outcome of patients with alpha-mannosidosis – A single center study